XRAY Quarterly Digest Spring 2020

Our partners and colleagues at For the Breast of Us have written a guide on how to be an accomplice for women of color affected by breast cancer. Please read and share this blog with your community.

Lynparza may improve outcomes for women with metastatic breast cancer, including those with an inherited PALB2 mutation. Women with an acquired tumor mutation in BRCA1 or BRCA2 also benefited. Read our XRAY-Behind the metastatic breast cancer headlines.

The FDA approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This approval includes treatment of people whose breast cancer has spread to the brain. Read more about the treatment behind the cancer headlines.

The FDA approved the first drug combination for first-line maintenance therapy for some women with advanced ovarian cancer. The approval was based on the ongoing PAOLA-1 clinical trial. Read our XRAY-Behind the ovarian cancer headlines.

The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. Read more behind the cancer headlines.

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy option for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy.